Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BIBF0775
Cat. No.:
OB0225LY-0202
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
BIBF0775 is a multi-targeted tyrosine kinase inhibitor primarily used to inhibit angiogenesis.
Synonym:
334951-90-5; (Z)-N-Ethyl-N-methyl-2-oxo-3-(phenyl((4-(piperidin-1-ylmethyl)phenyl)amino)methylene)indoline-6-carboxamide; 1H-Indole-6-carboxamide, N-ethyl-2,3-dihydro-N-methyl-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-, (3Z)-; (3Z)-N-Ethyl-N-methyl-2-oxo-3-[phenyl-[4-(piperidin-1-ylmethyl)anilino]methylidene]-1H-indole-6-carboxamide
CAS No.:
334951-90-5
Compound CID:
135837779
Formula:
C31H34N4O2
Formula Weight:
494.63
Specification
Relative Density:
1.223 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BIBF0775 can be used to study tumor-associated angiogenic processes and their role in tumor progression.
Library Information
Targets:
TGF-beta/Smad
Receptors:
TGFβR1
Pathways:
Angiogenesis; Tyrosine kinase/adaptors; Stem cells
Plate Number:
AOCL-3
Plate Location:
e6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
11 mg/mL; 22.24 mM
